A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.

Autor: Monane M; C2N Diagnostics, LLC, St. Louis, Missouri, USA., Johnson KG; Department of Psychiatry & Behavioral Sciences, Duke University, Durham, North Carolina, USA., Snider BJ; Washington University School of Medicine, St. Louis, Missouri, USA., Turner RS; Georgetown University School of Medicine, Washington, DC, USA., Drake JD; Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA., Maraganore DM; Department of Neurology, Tulane University School of Medicine, New Orleans, Louisiana, USA., Bicksel JL; Capital Neurology Services, McLean, Virginia, USA., Jacobs DH; Neurology Services of Orlando, Orlando, Florida, USA., Ortega JL; C2N Diagnostics, LLC, St. Louis, Missouri, USA., Henderson J; C2N Diagnostics, LLC, St. Louis, Missouri, USA., Jiang Y; Stat4ward, Pittsburgh, Pennsylvania, USA., Huang S; Stat4ward, Pittsburgh, Pennsylvania, USA., Coppinger J; C2N Diagnostics, LLC, St. Louis, Missouri, USA., Fogelman I; C2N Diagnostics, LLC, St. Louis, Missouri, USA., West T; C2N Diagnostics, LLC, St. Louis, Missouri, USA., Braunstein JB; C2N Diagnostics, LLC, St. Louis, Missouri, USA.

Publikováno v: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2023 Oct; Vol. 10 (10), pp. 1738-1748. Date of Electronic Publication: 2023 Aug 07.